ArticleClinical and translational radiation oncology2021
Development and results of a patient-reported treatment experience questionnaire on a 1.5 T MR-Linac.
Article in Clinical and translational radiation oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06965101 (Rapid Response MRI-Guided Palliative Radiotherapy), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rapid Response MRI-Guided Palliative Radiotherapy
Who cites it
18 citing papers in PubMed.
- MR-guided ultra-hypofractionated radiotherapy for early-stage glottic cancer: A phase I feasibility study.Clinical and translational radiation oncology · 2027Article
- Prospective controlled study comparing patient-reported outcomes after daily online adaptive radiotherapy or conventional IGRT in patients with prostate cancer.Clinical and translational radiation oncology · 2026Article
- Long-term patient experience with online MR-guided radiotherapy: adaptive versus non-adaptive workflow.Frontiers in oncology · 2026Article
- Evaluating participant experiences and tolerability with MR Linac imaging.Technical innovations & patient support in radiation oncology · 2025Article
- Optimizing Workflow for Cone Beam Computed Tomography-Based Online Adaptive Radiation Therapy Toward Reduced Physician Involvement.Advances in radiation oncology · 2025Article
- Patient experience of head and neck treatment on a 1.5 T MR-Linac: is the ATS-lite adaptive solution tolerable?Technical innovations & patient support in radiation oncology · 2025Article
- Treatment of Non-Hodgkin Lymphoma Involving Head and Neck Sites with a 1.5 T MR-Linac: Preliminary Results from a Prospective Observational Study.Hematology reports · 2025Article
- ESTRO guidelines for developing questionnaires in survey-based radiation oncology research.Clinical and translational radiation oncology · 2025Review
- Study protocol: Optimising patient positioning for the planning of accelerated partial breast radiotherapy for the integrated magnetic resonance linear accelerator: OPRAH MRL.Radiation oncology (London, England) · 2024Article
- On Patient Experience and Anxiety During Treatment With Magnetic Resonance-Guided Radiation Therapy.Advances in radiation oncology · 2024Article
- Patient expectation and experience of MR-guided radiotherapy using a 1.5T MR-Linac.Technical innovations & patient support in radiation oncology · 2024Article
- Prospective evaluation of patient-reported anxiety and experiences with adaptive radiation therapy on an MR-linac.Technical innovations & patient support in radiation oncology · 2024Article
- Magnetic resonance image-guided adaptive radiotherapy enables safe CTV-to-PTV margin reduction in prostate cancer: a cine MRI motion study.Frontiers in oncology · 2024Article
- MRI-Guided Radiation Therapy for Prostate Cancer: The Next Frontier in Ultrahypofractionation.Cancers · 2023Review
- The future of MRI in radiation therapy: Challenges and opportunities for the MR community.Magnetic resonance in medicine · 2022Review
- Online MR guided dose escalated radiotherapy for organ preservation in distal rectal cancer.Clinical and translational radiation oncology · 2022Article
- First Experience and Prospective Evaluation on Feasibility and Acute Toxicity of Online Adaptive Radiotherapy of the Prostate Bed as Salvage Treatment in Patients with Biochemically Recurrent Prostate Cancer on a 1.5T MR-Linac.Journal of clinical medicine · 2022Article
- Local control and patient reported outcomes after online MR guided stereotactic body radiotherapy of liver metastases.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionWith the implementation of new radiotherapy technology, it is imperative that patient experience is investigated alongside efficacy and outcomes. This paper presents the development of a specifically designed validated questionnaire and a first report of international multi-institutional preliminary patient experience of MRI-guided adaptive radiotherapy (MRgART) on the 1.5 T MR-Linac (MRL).
methodsA patient experience questionnaire was developed and validated before being distributed to the Elekta MRL Consortium, to gather first patient-reported experience from participating centres worldwide. The final version of the questionnaire contains 18 questions covering a range of themes and was scored on a Likert scale of 0-3. Responses were post-processed so that a score of 0 represents a negative response and 3 represents the most favourable response. These results were analysed for patient-reported experience of treatment on the MRL. Results were also analysed for internal consistency of the questionnaire using Chronbach's Alpha and the questionnaire contents were validated for relevance using content validity indexes (CVI).
results170 responses were received from five centres, representing patients with a wide range of tumour treatment sites from four different countries. MRgART was well tolerated with an 84% favourable response across all questions and respondents. When analysed by theme, all reported the highest percentage of results in the favourable categories (2 and 3). Internal consistency in the questionnaire was high (Cronbach's α = 0.8) and the item-level CVI for each question was 0.78 or above and the Scale-level CVI was 0.93, representing relevant content.
conclusionThe developed questionnaire has been validated as relevant and appropriate for use in reporting experience of patients undergoing treatment on the MRL. The overall patient-reported experience and satisfaction from multiple centres within the Elekta MRL Consortium was consistently high. These results can reinforce user confidence in continuing to expand and develop MRL use in adaptive radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.